Recombinant Human Growth Hormone in the Treatment of Patients With Cystic Fibrosis
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
CONTEXT: Recombinant human growth hormone (rhGH) improves growth in patients with growth hormone deficiency or idiopathic short stature. Its role in patients with cystic fibrosis (CF) is unclear. OBJECTIVE: To review the effectiveness of rhGH in the treatment of patients with CF. METHODS: Medline and the Cochrane Central Register of Controlled Trials were searched from the earliest date through April 2010. Randomized controlled trials, observational studies, systematic reviews/meta-analyses, or case reports were included if rhGH therapy was administered to patients with CF and data on prespecified harms, intermediate outcomes, or final health outcomes were reported. When applicable, end points were pooled by using a random-effects model. The overall body of evidence was graded for each outcome as insufficient, low, moderate, or high. RESULTS: Ten unique controlled trials (n = 312) and 8 observational studies (n = 58) were included. On quantitative synthesis of controlled trials, several markers of pulmonary function, anthropometrics, and bone mineralization were significantly improved versus control. Results of single-arm observational studies for the aforementioned outcomes were generally supportive of findings in clinical trials. There is insufficient evidence to determine the effect of rhGH on intravenous antibiotic use during therapy, pulmonary exacerbations, health-related quality-of-life, bone consequences, or total mortality, but moderate evidence suggests that rhGH therapy reduces the rate of hospitalization versus control. CONCLUSIONS: rhGH improved almost all intermediate measures of pulmonary function, height, and weight in patients with CF. Improvements in bone mineral content are also promising. However, with the exception of hospitalizations, the benefits on final health outcomes cannot be directly determined at this time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis
Konstan, M. W., Butler, S. M., Wohl, M. E. B., Stoddard, M., Matousek, R., Wagener, J. S., Johnson, C. A., & Morgan, W. J. (2003) · The Journal of Pediatrics · doi:10.1067/mpd.2003.152 · Cited by 393
Stature as a prognostic factor in cystic fibrosis survival
BEKER, L. T., RUSSEK-COHEN, E., & FINK, R. J. (2001) · Journal of the American Dietetic Association · doi:10.1016/s0002-8223(01)00113-4 · Cited by 179
Cited by
Turck, D., Braegger, C. P., Colombo, C., Declercq, D., Morton, A., Pancheva, R., Robberecht, E., Stern, M., Strandvik, B., Wolfe, S., et al. (2016) · Clinical Nutrition · doi:10.1016/j.clnu.2016.03.004 · Cited by 526
Wong, S. C., Dobie, R., Altowati, M. A., Werther, G. A., Farquharson, C., & Ahmed, S. F. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1026 · Cited by 163
Diagnosis and treatment of endocrine comorbidities in patients with cystic fibrosis
Siwamogsatham, O., Alvarez, J. A., & Tangpricha, V. (2014) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000096 · Cited by 36
A surveillance system to assess the need for updating systematic reviews
Ahmadzai, N., Newberry, S. J., Maglione, M. A., Tsertsvadze, A., Ansari, M. T., Hempel, S., Motala, A., Tsouros, S., Schneider Chafen, J. J., Shanman, R., et al. (2013) · Systematic Reviews · doi:10.1186/2046-4053-2-104 · Cited by 33
Growth and Growth Hormone Treatment in Children with Chronic Diseases
Pozzo, A. M., & Kemp, S. F. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.07.001 · Cited by 9
Metadata
- Authors
- Phung, O. J., Coleman, C. I., Baker, E. L., Scholle, J. M., Girotto, J. E., Makanji, S. S., Chen, W. T., Talati, R., Kluger, J., & White, C. M.
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2010-11-01
- Volume
- 126
- Issue
- 5
- Pages
- e1211-e1226
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2123616746
- Cited by
- 39
- References
- 2
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.